iCoat Medical’s product portfolio addresses several health issues that are connected to ischemia reperfusion injury. The table below shows what stage each product candidate has reached in the development cycle.
Trials
Ongoing:
- ATMIRe – This First-in-Human trial is a double-blind, placebo-controlled, randomized, single center trial to evaluate the safety, tolerability of ex vivo kidney allograft treatment with TUM012. The trial will include up to 18 patients.
In planning:
- EMPIRE Pilot – a randomized, placebo-controlled, double-blinded Phase-II trial, evaluating TUM012 efficacy to minimize IR Injury in Deceased-Donor Kidney Transplantation. Anticipated start: Q4 2023
- EMPIRE Pivotal – a phase-III trial designed to establish the efficacy of TUM012. Anticipated start: Q4 2024
For further information, see the press releases.
Pharmaceutical products
Candidate / Project
Usage area
Research
Preclinical studies
Clinical preparation
Phase I
Phase 2
Phase 3
Expected next step
iCoat Medical’s technology platform
TUM012
Kidney transplantation
Data readout – Q2-Q3 2023
Heart transplantation
Development plan completed – Q1 2023
Cardiopulmonary bypass – open heart surgery
Development plan completed – Q1 2023
Lung transplantation
Ongoing research
TUM020
Stroke
Ongoing
research
research
Myocardial infarction
Cardiopulmonary bypass – open heart surgery
Completed
Ongoing
Planning